Search results for: Rabbit Anti-Human CD290 Antibodies
#28729851 
2017/07/21
Save this
To Up
Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta.
To develop and validate a method for the detection of binding anti-drug antibodies (ADAs) against interferon beta (IFN-β) in human serum as part of a European initiative (ABIRISK) aimed at the prediction and analysis of clinical relevance of anti-biopharmaceutical immunization to minimize the risk.
1071 related Products with: Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta.
Rabbit Anti-Rat Androgen
Rat monoclonal anti mouse
Mouse Anti-Human CG beta
Mouse Anti-Human CG beta
Mouse Anti-Human IFN-beta
Mouse Anti-Human IFN-beta
Mouse Anti-Human IL-1 bet
Mouse Anti-Human IL-1 bet
Mouse Anti-Human MIP-3 be
Mouse Anti-Human MIP-3 be
Rat Anti-Mouse TCR V beta
Rat Anti-Mouse TCR V beta
Related Pathways
#28198767 2017/02/15
Save this
To Up
Anti-Gal and Anti-Neu5Gc Responses in Nonimmunosuppressed Patients After Treatment With Rabbit Antithymocyte Polyclonal IgGs.
Polyclonal antihuman thymocyte rabbit IgGs (antithymocyte globulin [ATG]) are popular immunosuppressive drugs used to prevent or treat organ or bone-marrow allograft rejection, graft versus host disease, and autoimmune diseases. However, animal-derived glycoproteins are also strongly immunogenic and rabbit ATG induces serum sickness disease in almost all patients without additional immunosuppressive drugs, as seen in the Study of Thymoglobulin to arrest Type 1 Diabetes (START) trial of ATG therapy in new-onset type 1 diabetes. 2896 related Products with: Anti-Gal and Anti-Neu5Gc Responses in Nonimmunosuppressed Patients After Treatment With Rabbit Antithymocyte Polyclonal IgGs.
Anti Galectin(Gal-3) Huma
Anti Galectin(Gal 3) Huma
Anti Galectin(Gal 3) Huma
Polyclonal Rabbit Anti In
Rabbit Anti-NOS-2 iNOS Po
Rabbit Anti-NOS-2 iNOS Po
Rabbit Anti-NOS-2 iNOS Po
Rabbit Anti-NOS-2 iNOS Po
Rabbit Anti-NOS-2 iNOS Po
Rabbit Anti-NOS-2 iNOS Po
Rabbit Anti-NOS-2 iNOS Po
Rabbit Anti-NOS-2 iNOS Po
Related Pathways
#27734678 2016/10/13
Save this
To Up
Electrochemical Sandwich Immunosensor for Determination of Exosomes Based on Surface Marker-Mediated Signal Amplification.
Extracellular vesicles (EVs), namely, exosomes and microvesicles, are important mediators of intercellular communication pathways. Since EVs can be detected in a variety of biofluids and contain a specific set of biomarkers which are reminiscent of their parental cells, they show great promise in clinical diagnostics as EV analysis can be performed in minimally invasive liquid biopsies. However, reliable, fast and cost-effective methods for their determination are still needed, especially if decentralized analysis is intended. In this study, we developed an electrochemical biosensor which works with 1.5 μL sample volume and can detect as low as 200 exosomes per microliter, with a linear range spanning almost 4 orders of magnitude. The sensor is specific and readily differentiates exosomes from microvesicles in samples containing 1000-fold excess of the latter. Capability of detecting exosomes in real samples (diluted serum) was shown. This was achieved by immobilizing rabbit antihuman CD9 antibodies on gold substrates and using monoclonal antibodies against CD9 for detection of captured exosomes. Signal amplification is presumably obtained from the fact that multiple detector antibodies bind to the surface of each captured vesicle. Detection is performed based on electrochemical reduction of 3,3',5,5'-tetramethyl benzidine (TMB) after addition of horseradish peroxidase (HRP)-conjugated anti-IgG antibodies. This amperometric biosensor can be easily incorporated into future miniaturized and semiautomatic devices for EV determination. 2238 related Products with: Electrochemical Sandwich Immunosensor for Determination of Exosomes Based on Surface Marker-Mediated Signal Amplification.
QuantiChrom™ LDH Cytoto
QuantiChrom™ Formaldehy
MarkerGeneTM Fluorescent
Cellufine Formyl , 50 ml
Cellufine Formyl Media
Cellufine Formyl , 500 ml
Cellufine Formyl Media
Cellufine Formyl Media
Bcl-2 Oncoprotein; Clone
Bcl-2 Oncoprotein; Clone
c-erbB-2 Oncoprotein
c-erbB-2 Oncoprotein
Related Pathways
#27667773 2016/09/26
Save this
To Up
An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.
Nivolumab, a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has activity in melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), and Hodgkin lymphoma. Nivolumab is approved in the USA and EU for advanced melanoma, NSCLC, and RCC, and relapsed Hodgkin lymphoma in the USA. Programmed death-ligand 1 (PD-L1), a PD-1 ligand, is expressed on mononuclear leukocytes, myeloid cells, and tumor cells. PD-L1 is being investigated as a potential biomarker to predict the association of tumor PD-L1 expression with nivolumab efficacy. 1318 related Products with: An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.
Alkaline Phospatase (ALP)
Cultrex In Vitro Angiogen
Multiple organ tumor tiss
Goat Anti-Human CLCA1 (aa
Anti-HBeAg (HBeAb) test s
Anti-HBcAg (HBcAb) test s
HCV antibody test strip,
H. Pylori antibody test s
H. Pylori antigen test ca
Malaria pan antigen test,
Malaria pf antigen test,
Malaria pf pv antigen tes
Related Pathways
#27362307 2016/06/30
Save this
To Up
Preemptive CD20+ B cell Depletion Attenuates Cardiac Allograft Vasculopathy in CD154-Treated Monkeys.
Anti-CD154 monotherapy is associated with antidonor allo-antibody (Ab) elaboration, cardiac allograft vasculopathy (CAV), and allograft failure in preclinical primate cell and organ transplant models. In the context of calcineurin inhibitors (CNI), these pathogenic phenomena are delayed by preemptive "induction" B cell depletion. 1213 related Products with: Preemptive CD20+ B cell Depletion Attenuates Cardiac Allograft Vasculopathy in CD154-Treated Monkeys.
CELLKINES Natural Human I
Leptin ELISA Kit, Rat Lep
Cultrex 24 Well BME Cell
Cultrex96 Well 3D BME Cel
baculoGROW insect cell me
Cell cycle antibody array
Cell Cycle Control Phosph
Cell Cycle Phospho-Specif
T-Cell Receptor Signaling
Rabbit Anti-Cell death in
InstantOne ELISA Cell Lys
MarkerGeneTM in vivo lacZ
Related Pathways
#27049528 2016/04/27
Save this
To Up
Poly(glycidyl methacrylate-co-2-hydroxyethyl methacrylate) Brushes as Peptide/Protein Microarray Substrate for Improving Protein Binding and Functionality.
We developed a three-dimensional (3D) polymer-brush substrate for protein and peptide microarray fabrication, and this substrate was facilely prepared by copolymerization of glycidyl methacrylate (GMA) and 2-hydroxyethyl methacrylate (HEMA) monomers via surface-initiated atom transfer radical polymerization (SI-ATRP) on a glass slide. The performance of obtained poly(glycidyl methacrylate-co-2-hydroxyethyl methacrylate) (P(GMA-HEMA)) brush substrate was assessed by binding of human IgG with rabbit antihuman IgG antibodies on a protein microarray and by the determination of matrix metalloproteinase (MMP) activities on a peptide microarray. The P(GMA-HEMA) brush substrate exhibited higher immobilization capacities for proteins and peptides than those of a two-dimensional (2D) planar epoxy slide. Furthermore, the sensitivity of the P(GMA-HEMA) brush-based microarray on rabbit antihuman IgG antibody detection was much higher than that of its 2D counterpart. The enzyme activities of MMPs were determined specifically with a low detection limit of 6.0 pg mL(-1) for MMP-2 and 5.7 pg mL(-1) for MMP-9. By taking advantage of the biocompatibility of PHEMA, the P(GMA-HEMA) brush-based peptide microarray was also employed to evaluate the secretion of MMP-2 and MMP-9 by cells cultured off the chip or directly on the chip, and satisfactory results were obtained. 2204 related Products with: Poly(glycidyl methacrylate-co-2-hydroxyethyl methacrylate) Brushes as Peptide/Protein Microarray Substrate for Improving Protein Binding and Functionality.
Carboxyfluorescein diacet
Rabbit Anti-Rat Androgen
EpiQuik General Protein D
EpiQuik General Protein
Acyl CoA binding Protein
E. coli SSB (Single Stran
E. coli SSB (Single Stran
E. coli SSB (Single Stran
E. coli SSB (Single Stran
Taq SSB (Single Stranded
Taq SSB (Single Stranded
Bone Morphogenetic Protei
Related Pathways
#26124191 2015/09/15
Save this
To Up
Unexpected Toxicology Findings in Rats Dosed With an Antihuman IL-13 Monoclonal Antibody.
Interleukin 13 (IL-13) is a type 2 helper T cytokine involved in allergic inflammation and immune responses to parasites. CNTO5825 is an antihuman IL-13 monoclonal antibody that inhibits the pharmacological activity of human, cynomolgus monkey, and rat IL-13. Repeated dose toxicology studies of 1- to 6-month duration were conducted in both rats and monkeys at doses of 20 to 100 mg/kg/wk. A decrease in the T cell-dependent antibody response to Keyhole Limpet Hemocyanin immunization was observed in monkeys but not in rats. In the 6-month rat study, there was a 2.2-fold increase in eosinophils in males at 3 and 6 months that was reversible. At necropsy (main and 4-month recovery), rats from control and CNTO5825-dosed groups were found to have pin worms, which may have contributed to the elevations in eosinophil. Testicular toxicity (dilatation of seminiferous tubules, atrophy, and degeneration of the germinal epithelium) was observed in 2 rats at 20 mg/kg and in 5 rats at 100 mg/kg (main and recovery). Brain lesions (unilateral focal accumulation of cells in the white matter of the cerebral cortex) were observed in 2 rats at 100 mg/kg, and vascular neoplasms (1 fatal multicentric hemangiosarcoma and 1 benign hemangioma) were observed at 100 mg/kg/wk. Overall, these studies show that CNTO5825 was without toxicity when administered to rats for up to 6 weeks and to monkeys for up to 6 months. However, when administered to rats for 6 months, a number of seemingly unrelated events occurred that could not be clearly linked to CNTO5825 administration, inhibition of IL-13, or to the immunological status of the animals. 1976 related Products with: Unexpected Toxicology Findings in Rats Dosed With an Antihuman IL-13 Monoclonal Antibody.
Anti AGO2 Human, Monoclon
Anti AGO2 Mouse, Monoclon
Anti AGO2 Human, Monoclon
Anti AGO2 Mouse, Monoclon
HIV1 integrase antibody,
Anti 3 DG imidazolone Mon
IL 13 Antibody
IL-13 Antibody
IL 13 Antibody
Mouse Anti-Insulin(1G11)
Mouse Anti-Insulin(1G11)
Mouse Anti-Insulin(1G11)
Related Pathways
#25613617 2015/01/23
Save this
To Up
[Functional analysis of cancer-derived immunoglobulin G whole molecule-interacting proteins identified by LC-MS/MS].
To identify cancer-derived immunoglobulin G (IgG) whole molecule-interacting proteins to provide important clues for studying IgG biological functions. 1882 related Products with: [Functional analysis of cancer-derived immunoglobulin G whole molecule-interacting proteins identified by LC-MS/MS].
Anti Rabbit IgG (H+L), un
Peroxidase~anti rabbit Ig
FITC conj. anti rabbit Ig
TRIT Cconj.anti rabbit Ig
Anti Goat IgG (H+L), Aff.
Peroxidase conj anti goat
Anti Human IgG (H+L), Aff
FITC conj.anti Human IgG
CELLKINES PLATELET DERIVE
PLATELET DERIVED GROWTH F
CELLKINES PLATELET DERIVE
PLATELET DERIVED GROWTH F
Related Pathways
#25604721 2015/03/26
Save this
To Up
Efficacy of porcine antihuman lymphocyte immunoglobulin compared to rabbit antithymocyte immunoglobulin as a first-line treatment against acquired severe aplastic anemia.
Immunosuppressive therapy (IST) with antithymocyte immunoglobulin (ATG) or antilymphocyte immunoglobulin (ALG) and cyclosporine A (CsA) is the treatment of choice against severe aplastic anemia (SAA) worldwide. However, a comparison of the efficacy of porcine ALG (pALG) and rabbit ATG (rATG) as a first-line treatment for acquired SAA has not been reported. In the present study, we retrospectively analyzed SAA patients treated with either pALG (n = 43) or rATG (n = 32) and compared their hematologic responses and survivals. There were no significant differences in overall response (OR) rates between pALG and rATG groups at 3 months (OR 41.86 versus 40.62% (P = 0.914), 6 months (OR 66.67 versus 61.29% (P = 0.635), 9 months (OR 69.05 versus 61.29% (P = 0.490), or 12 months (OR 69.05 versus 64.51% (P = 0.684), respectively. The OR rates in patients with SAA or very severe aplastic anemia (vSAA) in both groups were similar after a 12-month treatment (pALG 74.07 versus 60.00%, P = 0.550; rATG 70.00 versus 54.55%, P = 0.640). Patients who experienced <30-day interval between diagnosis and treatment displayed higher OR rates (at 12 months) than those with intervals ≥30 days (pALG 83.33 versus 50.00%, P = 0.021; rATG 87.50 versus 40.00%, P = 0.006). There were no significant differences in 2-year overall survival (OS) between pALG (87.4 ± 6.2%) and rATG (83.2 ± 7.8%) (P = 0.493). Infection was the major cause of death in both groups. In summary, pALG + CsA showed similar efficacy as rATG + CsA, as a first-line treatment for acquired SAA. 2408 related Products with: Efficacy of porcine antihuman lymphocyte immunoglobulin compared to rabbit antithymocyte immunoglobulin as a first-line treatment against acquired severe aplastic anemia.
immunoglobulin superfamil
Mouse anti-porcine type I
Mouse anti-porcine type I
Rat anti-porcine type I c
Rat anti-porcine type I c
Human monkey anti-porcine
Human monkey anti-porcine
Human monkey anti-porcine
ASK1 (Phospho Ser83) Anti
ASK1 (Phospho Ser966) Ant
Amplite™ Fluorimetric G
Rabbit Anti-alpha-Tocophe
Related Pathways
#25420810 2014/11/25
Save this
To Up